Navigation Links
Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
Date:6/2/2008

Monogram announces availability of HERmark and HER1 and HER3 Total Protein

Assays in Collaborative Biomarker Study

SOUTH SAN FRANCISCO, Calif., June 2 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that scientific collaborators have presented additional clinical results on HERmark(TM), the company's novel oncology assay, as a means to measure HER2 total protein and homodimer levels and predict response to Herceptin(R) (trastuzumab) in patients with metastatic breast cancer at the 44th ASCO Annual Meeting taking place in Chicago, Illinois. Monogram also announced the initiation of a Collaborative Biomarker Study involving the company's HERmark Breast Cancer Assay and the HER1 and HER3 Total Protein Assays.

"HERmark is the first diagnostic built upon our VeraTag technology," said Monogram CEO Bill Young. "Today we are announcing two developments that will elevate the profile of HERmark in the oncology community. First, important clinical data presented today demonstrates the superiority of HERmark over FISH testing for HER2. Second, we are initiating a study that will provide an opportunity for participating oncologists to experience first hand the superiority of HERmark in their clinical practices. We look forward to completing our commercial planning and to a future commercial launch of HERmark throughout the U.S."

HERmark Clinical Data

The oral presentation, entitled "Total HER2 and HER2 Homodimer Levels Predict Response to trastuzumab," discussed the findings of a study that investigated the HERmark assay's ability to identify and discriminate among patients with metastatic breast cancer who experienced different degrees of response to trastuzumab. The stu
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
2. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
3. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
4. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
5. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
6. Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
7. Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
8. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
9. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
10. Monogram Biosciences to Present at the Piper Jaffray 19th Annual Healthcare Conference
11. Monogram Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... MA and Pittsburgh PA (PRWEB) September 30, 2014 ... Clinical Research Nurses ( IACRN), a non-profit ... Alliance for Clinical Research Excellence and Safety ... the signing of a strategic alliance agreement, setting ... IACRN’s vision is to enhance clinical research quality ...
(Date:9/29/2014)... forefront of diagnostics today, with imaging techniques like ... and NMR (nuclear magnetic resonance) increasing steeply over ... image resolution and quality still limit these techniques ... solution is hyperpolarization, which involves injecting the patient ... following the distribution and fate of specific molecules ...
(Date:9/29/2014)... , Sept. 29, 2014  Ten of the ... of cartilage repair, regeneration, allograft reconstruction and research ... the world gathered to discuss the future of ... of Regenerative Medicine symposium, Cartilage Regeneration: State ... included Orthopedic Biosurgery, Minced Juvenile Allograft, and State ...
(Date:9/29/2014)... , Sept. 29, 2014 /PRNewswire/ - Portage Biotech Inc. ... PBT.U), is pleased to announce that its three Promissory ... Portage, who advanced $ 100,000 each in July 2014 ... their Notes and related Coupons converted into 3,500,001 restricted ... carried 5% coupon. Both the Note and the coupon ...
Breaking Biology Technology:IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3
... and Clinical Studies Demonstrate Activity of ... Agent against Gram-Positive Bacteria, CHICAGO, Sept. 18 ... THRX ) announced today results with the,investigational ... skin and skin structure infections,(cSSSIs) from a controlled ...
... Preclinical Animal Data Demonstrates Selective Survival Advantage of ... ZFN-Treated Immune Cells after HIV Infection, ... (Nasdaq: SGMO ) announced today the presentation of ... resistant to,HIV infection by treatment with zinc finger DNA-binding ...
... Research - the New ISI Web of Knowledge - ... Institutions Throughout the Country, PHILADELPHIA and LONDON, Sept. ... TOC ; TSX: TOC) and,leading provider of information ... that Spain,s La Fundacion Espanola,para la Ciencia y la ...
Cached Biology Technology:Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 2Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 3Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 4Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 5Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 6Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 2Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 3Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 4Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 5Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge 2Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge 3
(Date:9/29/2014)... , Sept. 29, 2014 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... S. Miceli has been named the Company,s Vice-President ... Gino Pereira as Chief Financial Officer. Mr. ... Executive Officer and as a Director. Mr. ...
(Date:9/29/2014)... safely tolerate treatment with cells cultured from human placental ... journal Multiple Sclerosis and Related Disorders . The ... conducted by researchers at Mount Sinai, Celgene Cellular Therapeutics ... institutions. , While designed to determine safety of ... that a preparation of cultured cells called PDA-001 may ...
(Date:9/28/2014)... by scientists at the University of California, Santa Cruz, ... within the genomes of primates drove the evolution of ... in every cell of our bodies. , The ... "retrotransposons" (a.k.a. "jumping genes") and the genes that have ... have, for the first time, identified genes in humans ...
Breaking Biology News(10 mins):NXT-ID, Inc. Names Vice-President and Chief Financial Officer 2NXT-ID, Inc. Names Vice-President and Chief Financial Officer 3Cells from placentas safe for patients with multiple sclerosis 2Human genome was shaped by an evolutionary arms race with itself 2Human genome was shaped by an evolutionary arms race with itself 3Human genome was shaped by an evolutionary arms race with itself 4
... is well known that animals use song as a way ... developed an unusual way of scaring off predators ?by singing ... Andrews discovered that wild gibbons in Thailand have developed a ... singing for survival, the gibbons appear to use the song ...
... replication within resident immune cells of the testis, providing ... even after effective highly active antiretroviral therapy. The related ... to human immunodeficiency virus-1 infection in situ and in ... of Pathology. , According to the most recent ...
... timing of food availability, researchers have identified the first ... Period 2, is a key component of the circadian ... of the University of Fribourg and Etienne Challet of ... 24th issue of the journal Current Biology, published by ...
Cached Biology News:Singing for survival 2Singing for survival 3Human testis harbors HIV-1 in resident immune cells 2Circadian gene helps the brain predict mealtime 2
Non-Receptor Tyrosine Kinase Sampler Kit 10 mu g each...
Hybridization chamblers suitable for use with all ChIP-GLAS microarrays....
Integrins Sampler Kit 10g each...
Protein Tyrosine Phosphatase Sampler Kit 10g each...
Biology Products: